Satsuma Pharmaceuticals (STSA) Stock Analysis

What Satsuma Pharmaceuticals does

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.

Key metrics

ETFs linked to STSA

Broad-market and Healthcare sector ETFs an investor holding Satsuma Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how STSA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals trades under the ticker STSA on NASDAQ.

Which exchange is STSA listed on?

STSA is listed on NASDAQ.

What sector does Satsuma Pharmaceuticals operate in?

Satsuma Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze STSA in a portfolio?

PortView shows STSA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.